Evidence map›Paper›PMID 30706121›Full record

ArticleEuropean radiology2019

Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer.

Lola-Jade Palmieri, Amina Fihri, Solène Doat, Olivier Dubreuil, Gilles Manceau, Mehdi Karoui, Mathilde Wagner, Olivier Lucidarme, Jean-Baptiste Bachet

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lola-Jade PalmieriGastroenterology and Digestive Oncology Department, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Amina FihriSorbonne University, Paris, France.
Solène DoatGastroenterology and Digestive Oncology Department, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Olivier DubreuilGastroenterology and Digestive Oncology Department, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Gilles ManceauSorbonne University, Paris, France.
Mehdi KarouiSorbonne University, Paris, France.
Mathilde WagnerSorbonne University, Paris, France.
Olivier LucidarmeSorbonne University, Paris, France. olivier.lucidarme@aphp.fr.ORCID http://orcid.org/0000-0003-0893-3764
Jean-Baptiste BachetGastroenterology and Digestive Oncology Department, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Sorbonne Université · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEarly tumor shrinkage (ETS) has been reported to be associated with survival of metastatic colorectal cancer (mCRC) patients. Our aim was to analyze long-term tumor-size evolution, according to early mCRC best responses during the first-line therapy, to evaluate first best response-survival links.

methodsSixty-five patients with unresectable mCRCs, treated between 2010 and 2015, were included retrospectively in this descriptive monocenter study and grouped according to their RECIST 1.1 first-line best responses: progressive disease (PD

resultsTumor loads of ETS

conclusionTumors responding to first-line chemotherapy also responded better to subsequent lines, whereas PD KEY POINTS: • Early shrinking tumors under first-line chemotherapy responded better to subsequent lines, maintaining low tumor loads, potentially explaining the link between early tumor shrinkage and overall survival of metastatic colorectal cancer (mCRC) patients. • mCRCs progressing under first-line chemotherapy remained refractory to other therapies and their tumor loads increased rapidly. • Even outside a clinical trial, an early first CT scan reevaluation with RECIST criteria 8 weeks after starting first-line therapy is crucial to determine long-term mCRC evolution.

Indexed as

AdultAgedAnalysis of VarianceAntineoplastic AgentsColorectal NeoplasmsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPredictive Value of TestsResponse Evaluation Criteria in Solid TumorsRetrospective StudiesTumor BurdenAntineoplastic AgentsColonic neoplasmsResponse evaluation criteria in solid tumorsSurvival rateTumor burden

Identifiers

PMID30706121
OpenAlexW2914966899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.